Literature DB >> 2864741

Does sulphasalazine cause folate deficiency in rheumatoid arthritis?

K A Grindulis, B McConkey.   

Abstract

Sulphasalazine impairs folic acid absorption and metabolism but rarely leads to folate deficiency in inflammatory bowel disease (IBD). In rheumatoid arthritis (RA), however, serum and red cell folate concentrations are often low and sulphasalazine might stress folate metabolism. In a prospective study, 2 g sulphasalazine was compared with 500 mg penicillamine daily in 30 patients over 24 weeks. Pre-treatment serum and red cell folate concentrations were low-normal. Improvements in disease activity and haemoglobin occurred in both treatment groups, but MCV increased only in patients taking sulphasalazine. Serum and red cell folate concentrations did not change in either group. Increased MCV with sulphasalazine might therefore reflect reticulocytosis secondary to drug-induced haemolysis. The mechanisms by which sulphasalazine antagonizes folate metabolism are dose-dependent and, consequently, higher doses might precipitate folate deficiency.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2864741     DOI: 10.3109/03009748509100404

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  11 in total

1.  Macrocytic anaemia in patients treated with sulfasalazine for rheumatoid arthritis.

Authors:  P Prouse; D Shawe; J M Gumpel
Journal:  Br Med J (Clin Res Ed)       Date:  1987-04-04

2.  Macrocytic anaemia in patients treated with sulphasalazine for rheumatoid arthritis.

Authors:  M Greaves; R S Amos; D Bax
Journal:  Br Med J (Clin Res Ed)       Date:  1987-02-07

3.  Macrocytic anaemia in patients treated with sulphasalazine for rheumatoid arthritis.

Authors:  P J Prouse; D Shawe; J M Gumpel
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-29

4.  Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis.

Authors:  C J Haagsma; H J Blom; P L van Riel; M A van't Hof; B A Giesendorf; D van Oppenraaij-Emmerzaal; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1999-02       Impact factor: 19.103

5.  Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods.

Authors:  R D Situnayake; K A Grindulis; B McConkey
Journal:  Ann Rheum Dis       Date:  1987-03       Impact factor: 19.103

Review 6.  Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis.

Authors:  C P Rains; S Noble; D Faulds
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

Review 7.  Sulphasalazine in arthritis--an old drug rediscovered.

Authors:  A J Taggart
Journal:  Clin Rheumatol       Date:  1987-09       Impact factor: 2.980

Review 8.  Disease-modifying antirheumatic drugs. Potential effects in older patients.

Authors:  G Gardner; D E Furst
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

9.  Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients.

Authors:  M Dougados; P Boumier; B Amor
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-11

10.  Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years.

Authors:  R S Amos; T Pullar; D E Bax; D Situnayake; H A Capell; B McConkey
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.